DOCSLIB.ORG

Financing Biomedical Ventures - Myths and Realities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Financing Biomedical Ventures - Myths and Realities Thèse n° 10 146 Financing Biomedical Ventures - Myths and Realities Présentée le 28 mai 2020 au Collège du management de la technologie Chaire de stratégie et innovation d’entreprise Programme doctoral en management de la technologie pour l’obtention du grade de Docteur ès Sciences par Jeffrey Scott BEHRENS Acceptée sur proposition du jury Prof. K. Younge, président du jury Prof. C. Tucci, directeur de thèse Prof. J. Krieger, rapporteur Prof. C. Mitteness, rapporteuse Prof. B. Clarysse, rapporteur 2020 Abstract Angel funding is an important source of capital for startup ventures (J. Sohl 2019), providing a similar level of capital as institutional venture capital (OECD 2011). But angel funding is challenging to study due to the informal nature of the activity. A common paradigm for new venture funding argues that new ventures initially fund their activities with angel investment and then, as they show success, make progress to commercialization and de-risk core venture propositions, ventures transition to more professional institutional (venture capital) funding. A belief in this paradigm can strongly influence early venture creation activities, and assumptions about the later availability of capital from institutional venture capital underpin many startup business plans. However, the literature exploring this phenomenon is very sparse, and the question of the relationship of angel to venture funding transition has rarely been studied. By analyzing a large and robust dataset, this thesis advances the understanding of the actual behavior of investors and the impact this early behavior, and the funding choices involved, have on company outcomes. This thesis also explores a novel form of venture investing and places it into a broader context of new venture funding that may help explain some of the key observations discussed. These fundamentally empirical studies examine the nature/reality of important entrepreneurial phenomena of interactions between angel and venture funding in novel ways, pose questions, and identify a set results that point to a potential market failure. Attempts are made to understand these results and place them into the contexts of both research theory and a broader understanding of entrepreneurial behavior; there certainly remain a set of unanswered questions and potential fruitful directions for future research. Keywords: Biomedical ventures, angel financing, venture capital, corporate venture capital 2 Acknowledgements Completing a PhD while running a biotech firm and launching an incubator is a daunting task. I am grateful for the ongoing support, encouragement, and critical feedback from Dr. Chris Tucci, my PhD Advisor. I also want to thank the following: • Steve Mortimer and Asher Schachter for R Programming support; • Dr. Joshua Krieger, Harvard Business School, for his insightful comments, discussion, and suggestions; • Dr. Cheryl Mitteness, Northeastern University, for her expertise in researching angel investment and helpful input throughout the process of writing this thesis; • Crunchbase (www.crunchbase.com), which provided access to their entire dataset under an academic research license; • The R programming language, R Studio, the R community, and key R packages (see Appendix for list); and • Lori Rutter, my very patient wife. 3 Table of Contents Chapter I. Introduction ........................................................................................................... 6 A. Overview of the Dissertation .................................................................................................... 6 B. Empirical Motivations and Research Questions ......................................................................... 7 C. Assumptions and Methodology ................................................................................................ 8 D. Contributions to the Literature ................................................................................................. 9 References for Chapter 1 ................................................................................................................ 10 Chapter 2: The A2VC Paradigm Fallacy: Path Dependency Creates Two Distinct World of Startup Financing ................................................................................................................. 11 A. Introduction ............................................................................................................................... 12 B. Background and Literature Review ............................................................................................. 14 C. Data Source and Methodology ................................................................................................... 18 D. A2VC Rate – Definition, Calculation, Analysis ............................................................................. 23 E. Success Rates ............................................................................................................................. 28 F. Discussion ................................................................................................................................... 30 G. Implications and Future Directions ............................................................................................. 34 H. Conclusion ................................................................................................................................. 36 References for Chapter 2 ................................................................................................................ 37 Appendix: R Language Details and Packages Used .......................................................................... 39 Chapter 3: Is Biotech VC Dead? ............................................................................................. 40 A. Tale of Two Venture Worlds ................................................................................................... 40 B. The Traditional VC Model Is Dead in Biotech: The Evidence .................................................... 41 C. A New Taxonomy .................................................................................................................... 43 D. How We Got Here ................................................................................................................... 43 E. Learning and VC Math ............................................................................................................ 44 F. Implications ............................................................................................................................ 45 G. Lessons for Other Industries ................................................................................................... 47 References For Chapter 3 ............................................................................................................... 48 Chapter 4: Is the Impact of Corporate Venture Capital Meaningful for Venture Outcomes? .. 49 Abstract ......................................................................................................................................... 49 A. Introduction and Literature Review ............................................................................................ 50 B. Data Source and Analytic Methodology ...................................................................................... 55 C. Data/Findings ............................................................................................................................. 58 4 D. Discussion .................................................................................................................................. 63 E. Conclusions and Future Research Opportunities ......................................................................... 65 Appendix – Summary Stats: US vs. ex-US ........................................................................................ 66 References for Chapter 4 ................................................................................................................ 67 Chapter 5: Conclusions .......................................................................................................... 69 A. Key Findings ........................................................................................................................... 69 B. Contributions to the Literature ............................................................................................... 69 C. Generalizability ....................................................................................................................... 70 D. Future Research Questions and Directions .............................................................................. 71 Consolidated References ....................................................................................................... 73 Jeff Behrens Curriculum Vitae ............................................................................................... 77 5 Chapter I. Introduction A. Overview of the Dissertation A common paradigm for new venture funding argues that new ventures initially fund their activities with angel investment and then, as they show success and grow, transition to more professional institutional venture funding. Angel funding is an important source of capital for startup ventures (J. Sohl 2019), providing a similar level of capital as institutional venture capital (OECD 2011). But angel funding is challenging to study, due to the
Load more

Recommended publications
  • JMP Securities Elite 80 Report (Formerly Super 70)
    Cybersecurity, Data Management & ,7 Infrastructure FEBRUARY 201 ELITE 80 THE HOTTEST PRIVATELY HELD &<%(5SECURITY, '$7$0$1$*(0(17 AND ,7,1)5$6758&785( COMPANIES &RS\ULJKWWLWLSRQJSZO6KXWWHUVWRFNFRP Erik Suppiger Patrick Walravens Michael Berg [email protected] [email protected] [email protected] (415) 835-3918 (415) 835-8943 (415)-835-3914 FOR DISCLOSURE AND FOOTNOTE INFORMATION, REFER TO JMP FACTS AND DISCLOSURES SECTION. Cybersecurity, Data Management & IT Infrastructure TABLE OF CONTENTS Executive Summary ............................................................................................................................ 4 Top Trends and Technological Changes ............................................................................................ 5 Funding Trends ................................................................................................................................ 11 Index by Venture Capital Firm .......................................................................................................... 17 Actifio ................................................................................................................................................ 22 Alert Logic ......................................................................................................................................... 23 AlgoSec ............................................................................................................................................ 24 AnchorFree ......................................................................................................................................
    [Show full text]
  • Database Software Market: Billy Fitzsimmons +1 312 364 5112
    Equity Research Technology, Media, & Communications | Enterprise and Cloud Infrastructure March 22, 2019 Industry Report Jason Ader +1 617 235 7519 [email protected] Database Software Market: Billy Fitzsimmons +1 312 364 5112 The Long-Awaited Shake-up [email protected] Naji +1 212 245 6508 [email protected] Please refer to important disclosures on pages 70 and 71. Analyst certification is on page 70. William Blair or an affiliate does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. This report is not intended to provide personal investment advice. The opinions and recommendations here- in do not take into account individual client circumstances, objectives, or needs and are not intended as recommen- dations of particular securities, financial instruments, or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. William Blair Contents Key Findings ......................................................................................................................3 Introduction .......................................................................................................................5 Database Market History ...................................................................................................7 Market Definitions
    [Show full text]
  • Private Companiescompanies
    PrivatePrivate CompaniesCompanies Private Company Profiles @Ventures Kepware Technologies Access 360 Media LifeYield Acronis LogiXML Acumentrics Magnolia Solar Advent Solar Mariah Power Agion Technologies MetaCarta Akorri mindSHIFT Technologies alfabet Motionbox Arbor Networks Norbury Financial Asempra Technologies NumeriX Asset Control OpenConnect Atlas Venture Panasas Autonomic Networks Perimeter eSecurity Azaleos Permabit Technology Azimuth Systems PermissionTV Black Duck Software PlumChoice Online PC Services Brainshark Polaris Venture Partners BroadSoft PriceMetrix BzzAgent Reva Systems Cedar Point Communications Revolabs Ceres SafeNet Certeon Sandbridge Technologies Certica Solutions Security Innovation cMarket Silver Peak Systems Code:Red SIMtone ConsumerPowerline SkyeTek CorporateRewards SoloHealth Courion Sonicbids Crossbeam Systems StyleFeeder Cyber-Ark Software TAGSYS DAFCA Tatara Systems Demandware Tradeware Global Desktone Tutor.com Epic Advertising U4EA Technologies ExtendMedia Ubiquisys Fidelis Security Systems UltraCell Flagship Ventures Vanu Fortisphere Versata Enterprises GENBAND Visible Assets General Catalyst Partners VKernel Hearst Interactive Media VPIsystems Highland Capital Partners Ze-gen HSMC ZoomInfo Invention Machine @Ventures Address: 187 Ballardvale Street, Suite A260 800 Menlo Ave, Suite 120 Wilmington, MA 01887 Menlo Park, CA 94025 Phone #: (978) 658-8980 (650) 322-3246 Fax #: ND ND Website: www.ventures.com www.ventures.com Business Overview @Ventures provides venture capital and growth assistance to early stage clean technology companies. Established in 1995, @Ventures has funded more than 75 companies across a broad set of technology sectors. The exclusive focus of the firm's fifth fund, formed in 2004, is on investments in the cleantech sector, including alternative energy, energy storage and efficiency, advanced materials, and water technologies. Speaker Bio: Marc Poirier, Managing Director Marc Poirier has been a General Partner with @Ventures since 1998 and operates out the firm’s Boston-area office.
    [Show full text]
  • Fidelity Insurance Group, Inc
    Fidelity Insurance Group, Inc. ww w.fidelityinsgroup.com/ Fidelity National Title Group (NYSE: FNF) FNF Title International FNF Title International is a subsidiary of Fidelity National Financial (New York Stock Exchange Symbol:FNF), and provides title insurance and indemnity for FNF's international customers. American Fidelity Assurance Company www.afadvantage.com/ We're a family-owned company providing supplemental insurance in four key industries: education, healthcare facilities, auto dealerships and municipalities. ... City and County Government: Just One of Our Specialties ***************** Fidelity Insurance Group, Inc. Fidelity Insurance Group provides a competitive offering of Jacksonville Insurance, Orange Park Insurance, and St. Augustine Insurance products including ... www.fidelityinsgroup.com/ - Cached - Similar Fidelity National Property and Casualty Insurance Group Fidelity National Property & Casualty Insurance Group: Your First Stop for All Your Insurance Needs. If you are a Fidelity Title/Escrow officer, ... www.fnicproducer.com/fnpac/index.html - Cached - Similar Am erican Fidelity Assurance Company : Main Site Content We're a family-owned company providing supplemental insurance in four key industries: education, healthcare facilities, auto dealerships and municipalities. ... www.afadvantage.com/ - Cached – Similar Claim Status Flex Claim Status • F AQs Please select a category or type your question in the box below All FAQs Contact us by phone: (800)654-8489 FIDELITY – FNF (Fidelity National Financial)-CORPORATION TRUST COMPANY -American Fidelity Assurance Company 1 of 39 © American Fidelity Assurance Company 2011 Home About AFA News Center Privacy Policy Terms of Use Licensing Site Map ***************** http://www.afadvantage.com/home.aspx http://www.afadvantage.com/for-employers/municipal.aspx City and County Government: Just One of Our Specialties Municipalities are unique in their insurance needs, with special considerations that should be carefully considered in an overall benefits plan.
    [Show full text]
  • Atlantic Drift Venture Capital Performance in the UK and the US
    Research report: June 2011 Atlantic Drift Venture capital performance in the UK and the US Josh Lerner, Yannis Pierrakis, Liam Collins and Albert Bravo Biosca NESTA is the UK’s foremost independent expert on how innovation can solve some of the country’s major economic and social challenges. Its work is enabled by an endowment, funded by the National Lottery, and it operates at no cost to the government or taxpayer. NESTA is a world leader in its field and carries out its work through a blend of experimental programmes, analytical research and investment in early- stage companies. www.nesta.org.uk Executive summary The importance of a vibrant venture capital Key findings industry in supporting growth is widely recognised, and consequently governments 1. The returns performance of UK and US VC across the world have sought to promote funds in recent years has been very similar. the industry. But the development of the VC UK funds have historically underperformed industry in the UK (and in many other countries) US funds, but this gap has significantly has been hampered by the low returns it delivers narrowed. The gap in fund returns (net to its investors. Understanding how the UK IRR) between the average US and UK fund venture capital market compares with other has fallen from over 20 percentage points ones, particularly the US market, is the first step before the dotcom bubble (funds raised towards improving the performance of the UK in 1990-1997) to one percentage point VC industry. afterwards (funds raised in 1998-2005). However, this convergence has been driven This report sheds further light on the by declining returns in the US after the magnitude of the performance gap between burst of the dotcom bubble, rather than US and UK venture capital funds, its evolution by increasing returns in the UK.
    [Show full text]
  • Business Plan Korzortia 2020
    Business Plan CONTENTS 1. INTRODUCTION........................................................................ 4 2. EXECUTIVE SUMMARY.................................................................. 5 3. FINANCIAL PLAN.......................................................................12 Forecast 12 Financial Highlights by Year 12 4. BUSINESS MODEL......................................................................18 a. Value Proposi�on 18 i. The Problem 18 ii. The Product 18 b. Channels 24 c. Customer Rela�ons 25 d. Partners 26 5. COMPANY SUMMARY.................................................................. 27 a. Vision 27 b. Mission Statement 27 c. Business Objec�ves 27 d. Registered Name and Corporate Structure 28 e. Company Ownership 28 i. Company Loca�on 29 ii. Risk Management 29 iii. Management Summary 30 Organiza�onal Chart................................................................... 32 6. THE MARKET.......................................................................... 33 a. Financial Markets 33 i. Crowdfunding 35 ii. NAO Stats 35 iii. NAOs 35 iv. Remi�ance 35 v. How Is the Interna�onal Money Transfer Market Evolving? 37 vi. Remi�ances: Fees are Falling and MTOs Dominate 38 vii. The Pressure to Lower Fees is Affec�ng MTOs 39 b. Target Market 40 i. Retail Investor Demographics 40 ii. Forex Technology Stats 40 iii. Forex Trader Stats 40 iv. Global Crowdfunding Market – Segmenta�on 41 v. Remi�ance 41 vi. Digital Exchange 42 c. Compe�tors 43 i. Crowdfunding 43 ii. Remi�ance Compe�tors 44 a. Stock/Forex Brokers/Money Managers 45 Compe��ve Analysis 46 7. COMPETITIVE ADVANTAGE............................................................. 49 a. Differen�a�on 49 b. SWOT Analysis 51 8. EXECUTION PLAN...................................................................... 52 002 Road Map 52 Key Ac�vi�es 52 Go-To Market Strategy 53 Financial Plan 55 9. FINANCIAL INFORMATION.............................................................. 57 a. Resources 57 b. Costs and Expenses 58 i. Konzor�a Capital 58 ii. InveStart 59 iii.
    [Show full text]
  • Organizing Venture Capital: the Rise and Demise of American Research & Development Corporation, 1946–1973
    Industrial and Corporate Change, Volume 14, Number 4, pp. 579–616 doi:10.1093/icc/dth064 Advance Access published June 21, 2005 Organizing venture capital: the rise and demise of American Research & Development Corporation, 1946–1973 David H. Hsu and Martin Kenney While venture capital (VC) has become an important element of the twentieth- century US innovation system, few studies have systematically examined the ori- gins and evolution of this financial institution. We take a step in this direction by analyzing the evolution of the early and influential VC firm, American Research & Development Corporation (ARD), in the period that it was independent from 1946 to 1973. We place the creation and subsequent evolution of ARD within its historical context and show how it was an innovation by Boston-area civic elites. Using new historical data, we examine the evolution of ARD’s practices over time. We argue that ARD’s funding model constrained its functioning as a venture capital firm and contributed to its demise. ARD was a pioneering organization whose business model ultimately failed as a newer organizational model, the limited partnership, was created and had a better fit with the business environment. Nevertheless, ARD has had a lasting imprint on the practice of modern venture capital. 1. Introduction This paper explores what during the Great Depression was a minor, almost footnote-size, response to the overall crisis, the creation of the venture capital firm. The 1929 stock market collapse was reflected and magnified in the bankruptcies of enormous num- bers of smaller firms as the financial system ground to a halt.
    [Show full text]
  • Full Version
    The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of ThinkGeek Network Technology Co., Ltd. (A company incorporated in the Cayman Islands with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Securities and Futures Commission solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its respective sponsors, advisers and members of the underwriting syndicate that: (a) this document is only for the purpose of providing information about the Company to the public in Hong Kong and not for any other purposes. No investment decision should be based on the information contained in this document; (b) the publication of this document or any supplemental, revised or replacement pages on the Stock Exchange’s website does not give rise to any obligation of the Company, its respective sponsors, advisers or members of the underwriting syndicate to proceed with an offering in Hong Kong
    [Show full text]
  • Putting Capital Back to Work the Receivables Exchange Creates a New Way for Small and Midsize Business to Manage Cash Flow
    Nicolas Perkin Putting Capital Back to Work The Receivables Exchange Creates a New Way for Small and Midsize Business to Manage Cash Flow Innovations Case Narrative: The Receivables Exchange I have always had a fascination with disruptive technologies, an inclination that has often led me to think about how we might disrupt the status quo or provide an innovation that favors a more efficient or convenient arrangement of the market- place. In the last 20 years, we have seen numerous disruptions that have forever transformed businesses and lifestyles—cell phones and computers are the most obvious examples. Despite these advances, the way small and midsize businesses (SMBs) secure capital has changed very little for many decades. My vision for modernizing accounts receivable and getting working capital into the hands of small and midsize businesses, together with my partner Justin Brownhill’s idea for an exchange and his experience with electronic trading technology, led to the establishment in 2007 of The Receivables Exchange, and the launch in November 2008 of the world’s first online capital marketplace for buying and selling accounts receivable. In doing so, we succeeded in providing a new solution to the age-old problem of cash flow that almost all businesses face. Moreover, by establishing our headquarters in New Orleans, we also have had the opportunity to play a central role in building the dynamic and entrepreneurial city that has emerged since Hurricane Katrina. The credit crisis of 2008 and 2009 made it nearly impossible for a business of any size to get access to capital, much less the millions of SMBs that took the brunt of the financial fallout.
    [Show full text]
  • Silicon Valley London Woodside Capital Partners (WCP)
    Silicon Valley London Woodside Capital Partners (WCP) proudly releases the inaugural healthcare report “State of Digital Health”. In 2016, healthcare cost in the US was $3.3 Trillion – 17.9% of GDP, passing $10,000 per capita mark for the first time ever. According to CMS, by 2026, the figure is projected to grow to $5.7 Trillion – 19.8% of GDP. The answer to curbing and reversing the trend with respect to healthcare costs lies in large part to the movement towards Digital Health, or ‘Health Tech’. The proliferation of devices and applications across the healthcare spectrum has led to a data tsunami – the “what”. Machine Learning, Artificial Intelligence and overall Big Data analytics are leading to real-time actionable insights – the “so what”. We have entered the realm of the Internet of Medical Things (IoMT), with ubiquitous connectivity and measurement of everything from our vitals and nutrition to physical activity and medical compliance. We are just starting to leverage that data in a meaningful way and seeing early impact on health and well-being. In 2017, venture investments in Digital Health startups exceeded $6 Billion for the first time, and the trend seems to be accelerating with $1.6 Billion invested in Q1, 2018. The juxtaposition of rising healthcare costs and increased Digital Health investments is not all that surprising. Advances in underlying real-time analytics and potential of leading edge innovations around genomics are turning the perceived fiction of personalized medicine into a real possibility. Foundational disruptions such as Blockchain, while relatively nascent, are creating excitement (and some anxiety) around secure, immutable data sharing across silos – with healthcare as the ideal use case.
    [Show full text]
  • Biotechnology Startups Research Report
    GLOBAL BUSINESS CONFIDENCE REPORT 4th Qtr. 2019 B IOTECH NOLOGY STARTUPS RESEARCH REPORT 4th Quarter 2019 www.tradecouncil.org www.qibcertification.org International Trade Council www.tradecouncil.org www.goglobalawards.org Page 1 MARKET OVERVIEW REPORT FOR ENTERPRISE ESTONIA Table of Contents Overview ........................................................................................................................................................................... 3 Industry Definition .......................................................................................................................................................................................... 3 Sectoral Definitions ........................................................................................................................................................................................ 3 Main Activities .................................................................................................................................................................................................. 4 Associated Industries ..................................................................................................................................................................................... 4 Industry at a Glance ......................................................................................................................................................... 5 Industry Overview ..........................................................................................................................................................................................
    [Show full text]
  • Venture Capital Funding, First Quarter 2014
    Venture Capital Funding Survey, First Quarter 2014 VENTURE CAPITAL FUNDING, FIRST QUARTER 2014 This is a listing of many of the Bay Area firms that received venture capital financing between Jan. 1 and March 31, 2014. Most of the data was compiled from a survey conducted by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association in conjunction with the Mercury News. In the case of some investments there may have been other participants in the round who are not credited. Also, the amounts listed may not include all venture funding the company received during the quarter. *Indicates this is a seed or first-round infusion of money from venture capitalists. These companies may have received money previously from other investors and aren't necessarily startups. BIOTECHNOLOGY / HEALTH Name City Stage Amount Investors Description 3-V Biosciences Menlo Park Early Stage $4,749,000 Kleiner Perkins Therapeutics that modulate Caufield & Byers, pathways for the treatment of New Enterprise oncology Associates Acerta Pharma San Carlos Startup/Seed $13,000,000 Frazier Healthcare, Treatments for cancer and undisclosed firm autoimmune diseases Afferent Pharmaceuticals San Mateo Early Stage $6,300,000 Domain Associates, Clinical-stage undisclosed firm biopharmaceutical company Altura Medical Menlo Park Expansion $4,000,000 SV Life Sciences Medical devices Advisers, undisclosed firm Atara Biotherapeutics Brisbane Early Stage $13,500,000 Amgen, Domain Drug development company Associates, Duff Ackerman & Goodrich, Kleiner
    [Show full text]